Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06480526 · ClinicalTrials.gov registry record
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
A clinical trial of High-risk Neuroblastoma, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT06480526: Recruiting study of High-risk Neuroblastoma, sponsored by St. Jude Children's Research Hospital.
NCT06480526 is a study of High-risk Neuroblastoma that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 45 participants, below the 60-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06480526, a study of High-risk Neuroblastoma, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital). Exploratory Objectives * To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy. * To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.
Primary Outcome
To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital). To establish the feasibility, we will estimate the participation rate. The study is considered to have an acceptable participation rate if the 95
Conditions Studied
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2028-12 |
What NCT06480526 shows while recruiting
NCT06480526 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 9 other High-risk Neuroblastoma trials with a reported enrollment target (25% lower).
The record links to 1 condition, with High-risk Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT06480526 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06480526 about?
NCT06480526 is a clinical study titled "Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors". The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) st...
What is the current status of trial NCT06480526?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2024-10-21. Estimated completion is 2028-12.
What conditions does trial NCT06480526 study?
This clinical trial studies the following conditions: High-risk Neuroblastoma.
Who is sponsoring clinical trial NCT06480526?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06480526 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-risk Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06480526's enrollment target sits among peer trials
45 5th of 9 higher than 3 of 9 other High-risk Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High-risk Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
RECRUITING · Phase 2
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
-
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
RECRUITING · Phase 2
-
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI